Cynata Therapeutics Bilan de santé

Santé financière contrôle des critères 4/6

Cynata Therapeutics possède un total de capitaux propres de A$7.2M et une dette totale de A$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont A$8.4M et de A$1.2M.

Informations clés

Ratio d'endettement

AU$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$6.21m
Fonds propres	AU$7.22m
Total du passif	AU$1.17m
Total des actifs	AU$8.39m

Mises à jour récentes de la santé financière

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Feb 02

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Sep 09

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

May 26

Recent updates

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Sep 21

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

May 29

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

Feb 09

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Feb 02

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Sep 09

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

May 26

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Dec 31

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Aug 11

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CYP ( A$6.5M ) dépassent ses passifs à court terme ( A$1.2M ).

Passif à long terme: CYP n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: CYP est sans dette.

Réduire la dette: CYP n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: CYP dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: CYP dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 17.9 % chaque année

Cynata Therapeutics Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Recent updates

Cynata Therapeutics Limited, Annual General Meeting, Nov 19, 2024

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

New major risk - Financial position

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial

Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001

New minor risk - Financial position

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

Cynata Therapeutics Limited Announces Resignation of David Atkins as Director

New major risk - Financial position

Cynata Therapeutics Limited Announces Management Appointments

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Cynata Therapeutics Limited Receives IRB Approval for Proposed aGvHD Phase 2 Clinical Trial

Cynata Therapeutics Limited Receives Notice of Acceptance from IP Australia for Novel Application of Cymerus MSCs

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Cynata Therapeutics Limited Receives Notice of Allowance for Australia & Canada Cymerus Patents

Cynata Therapeutics Limited Announces Successful Completion of Planned DSMB Review of DFU Trial

Cynata Therapeutics Limited, Annual General Meeting, Nov 22, 2022

Cynata Therapeutics Limited Receives Grant Award to Fund Study of Cynata Mscs in Heart Disease from Australian Government National Health and Medical Research Council

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Cynata Therapeutics Limited Appoints Janine Rolfe as Independent Non-Executive Director, Effective 1 September 2022

Cynata Therapeutics Limited Announces Preclinical Study Showing Optimisation of CymerusTM MSCs for Coronary Artery Disease Published in Leading Peer-Reviewed Journal

Cynata Therapeutics Limited Receives Notice of Allowance from US Patent Office for Use of the Cymerus MSCs in Asthma

Cynata Therapeutics Limited Announces the Completion of A Pre-Clinical Study That Has Provided Further Evidence in Support of the Highly Potent Anti-Inflammatory Effects of Cynata's Proprietary Cymerus MSCs

Cynata Therapeutics Limited Adds New Site for MEMD Clinical Trial

United States Food and Drug Administration Clears IND for Cynata Therapeutics Limited's Phase 2 Clinical Trial of CYP-001 in GvHD

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Price target decreased to AU$2.00

Cynata Therapeutics Limited Advances Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Cynata Therapeutics Limited Receives Decision to Grant A Patent in Japan

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Cynata Therapeutics Limited Commences DFU Clinical Trial

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Cynata Therapeutics Limited Receives Approval by the Central Adelaide Local Health Network Human Research Ethics Committee to Commence A Clinical Trial

Cynata Therapeutics Limited Progresses Toward Clinical Trial in Diabetic Foot Ulcers

Cynata Therapeutics Limited Announces First Patient Enrolled in Cynata Mend Clinical Trial

Cynata Therapeutics Limited to Investigate New Study of the High Potency of Cymerus MSCs

New 90-day low: AU$0.64

New 90-day low: AU$0.66

New 90-day low: AU$0.74

Cynata Therapeutics Limited Announces Phase 3 Osteoarthritis Clinical Trial Commences

Cynata Therapeutics Limited Announces Positive Efficacy Data from A Study of Cymerustm Mesenchymal Stem Cells

New 90-day high: AU$1.03

New 90-day high - AU$0.79

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines